- Home
- COLL vs KBDC Comparison
COLL vs KBDC Comparison
Compare COLL & KBDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | COLL | KBDC |
|---|---|---|
| Founded | 2002 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 980.7M |
| IPO Year | 2015 | 2018 |
Fundamental Metrics
Financial Performance| Metric | COLL | KBDC |
|---|---|---|
| Price | $33.19 | $14.32 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $51.40 | $15.50 |
| AVG Volume (30 Days) | ★ 384.8K | 201.9K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | ★ 13.16% |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.40 | ★ 0.43 |
| Revenue | ★ $780,567,000.00 | N/A |
| Revenue This Year | $8.01 | $193.84 |
| Revenue Next Year | N/A | $9.00 |
| P/E Ratio | $81.73 | ★ $33.79 |
| Revenue Growth | ★ 23.62 | N/A |
| 52 Week Low | $29.08 | $13.06 |
| 52 Week High | $50.79 | $16.28 |
Technical Indicators
Market Signals| Indicator | COLL | KBDC |
|---|---|---|
| Relative Strength Index (RSI) | 47.84 | 43.85 |
| Support Level | $31.56 | $14.02 |
| Resistance Level | $35.95 | $14.70 |
| Average True Range (ATR) | 1.20 | 0.29 |
| MACD | -0.15 | -0.07 |
| Stochastic Oscillator | 62.20 | 20.00 |
Price Performance
Historical ComparisonAbout COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.
About KBDC Kayne Anderson BDC Inc.
Kayne Anderson BDC Inc is an externally managed, closed-end, non-diversified management investment company that has elected to be regulated as a business development company, investing mainly in first-lien senior secured loans, with a secondary focus on unitranche and split-lien loans to middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation mainly through debt investments in middle-market companies.